A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis (Q61657837)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 July 2014

Language	Label	Description	Also known as
English	A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis	scientific article published on 16 July 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Helen J Lachmann

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

C P Venner

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

J D Gillmore

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

S Sachchithanantham

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

S Mahmood

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

T Lane

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

D Foard

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

L Rannigan

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

S D J Gibbs

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

J H Pinney

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

C J Whelan

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

P N Hawkins

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

A D Wechalekar

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

16 July 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

2304-2310

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25027514%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

https://scigraph.springernature.com/pub.10.1038/leu.2014.218

0 references

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal Transplantation in Systemic Amyloidosis-Importance of Amyloid Fibril Type and Precursor Protein Abundance

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological features of the clone involved in primary amyloidosis (AL).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome in Renal AL Amyloidosis After Chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25027514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Journal of Protein Folding Disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.218

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61657837&oldid=1970556113"